WASHINGTON – A new study published in Cancer Discovery, a monthly peer-reviewed medical journal released by the American Association for Cancer Research (AACR), has shown promising results from the phase 2 clinical trial of the drug, Trametinib, in treating relapsed or refractory (R/R) juvenile myelomonocytic leukaemia (JMML).
According to the study, seven out of the 10 patients had either objective response to treatment or experienced stable disease, with two complete responses and three partial responses.
The new discovery could prove to be an alternative to the most common JMML treatment, known as “allogeneic hematopoietic stem cell transplantation” (HSCT).
JMML is a very rare, aggressive form of childhood leukaemia caused by an overproduction of monocytes and immature white blood cells called blasts. (WAM)
